Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

June 30, 2021

Conditions

Knee Osteoarthritis

Interventions

BIOLOGICAL

Elixcyte 8 ml

ADSC 6.4\*10\^7 cells, allogeneic injection

DEVICE

Hya Joint Plus

Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.

BIOLOGICAL

Elixcyte 4 ml

ADSC 3.2\*10\^7 cells, allogeneic injection

BIOLOGICAL

Elixcyte 2 ml

ADSC 1.6\*10\^7 cells, allogeneic injection

Trial Locations (2)

Taipei Veterans General Hospital, Taipei

Chang Gung Memorial Hospital Linkou, Taoyuan

All Listed Sponsors

collaborator

A2 Healthcare Taiwan Corporation

INDUSTRY

lead

UnicoCell Biomed CO. LTD

INDUSTRY

NCT02784964 - Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis | Biotech Hunter | Biotech Hunter